Cytek Biosciences, Inc. (CTKB) — Financial statements
Income statement, balance sheet, and cash flow for Cytek Biosciences, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 201↑0.5% | 200↑3.9% | 193↑17.7% | 164↑28.2% | 128 | |
| Cost of Revenue | 97↑8.6% | 89↑6.9% | 84↑32.6% | 63↑29.2% | 49 | |
| Gross Profit | 104↓6.0% | 111↑1.5% | 109↑8.4% | 101↑27.6% | 79 | |
| Operating Expenses | ||||||
| R&D Expenses | 36↓7.4% | 39↓10.8% | 44↑26.7% | 35↑42.6% | 24 | |
| General & Administrative Expenses | 59↑36.7% | 43↓2.0% | 44↑26.8% | 35↑66.5% | 21 | |
| Selling & Marketing Expenses | 49↑0.7% | 49↓0.1% | 49↑47.9% | 33↑34.5% | 25 | |
| SG&A Expenses | 108↑17.5% | 92↓1.0% | 93↑37.1% | 68↑49.1% | 46 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 145↑10.0% | 132↓4.1% | 137↑33.6% | 103↑46.9% | 70 | |
| Total Costs & Expenses | 242↑9.5% | 221↑0.1% | 221↑33.2% | 166↑39.6% | 119 | |
| Operating Results | ||||||
| Operating Income | -40↓96.8% | -21↑26.3% | -28↓1443.5% | -2↓119.7% | 9 | |
| Depreciation & Amortization | 12↑14.2% | 10↑13.7% | 9↑63.1% | 6↑355.6% | 1 | |
| EBITDA | -17↓73.3% | -10↓127.6% | -4↓146.4% | 9↑6.4% | 9 | |
| EBIT | -29↓43.1% | -21↓50.5% | -14↓455.8% | 4↓50.1% | 8 | |
| Interest & Other Income | ||||||
| Net Interest Income | 2↓83.2% | 10↑138.6% | 4↑112.2% | 2↑220.9% | -2 | |
| Interest Income | 2↓78.6% | 10↑61.5% | 6↑38.8% | 5↑9326.5% | 0.05 | |
| Interest Expense | 0.47 | 0.00↓100.0% | 2↓19.5% | 3↑47.8% | 2 | |
| Non-Operating Income | -11 | 0.00↑100.0% | -14↓152.0% | -6↓481.4% | 1 | |
| Other Income / Expenses | 11↓28.9% | 15↑22.1% | 12↑296.1% | 3↑195.2% | -3 | |
| Income Before Tax | -30↓423.5% | -6↑63.7% | -16↓1346.7% | 1↓78.8% | 6 | |
| Income Tax Expense | 37↑11368.1% | 0.32↑109.0% | -4↓190.9% | -1↓142.0% | 3 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -67↓1005.3% | -6↑50.4% | -12↓589.0% | 2↓17.9% | 3 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -67↓1005.3% | -6↑50.4% | -12↓571.6% | 3↓14.2% | 3 | |
| Bottom-Line Net Income | -67↓1005.3% | -6↑50.4% | -12↓571.6% | 3 | 0.00 | |
| EPS (Basic) | -0.52↓1030.4% | -0.05↑48.8% | -0.09↓567.7% | 0.02↓41.8% | 0.03 | |
| EPS (Diluted) | -0.52↓1028.0% | -0.05↑48.7% | -0.09↓582.8% | 0.02↓43.6% | 0.03 | |
| Weighted Average Shares | 128↓2.2% | 131↓3.5% | 135↑0.6% | 135↑0.6% | 134 | |
| Weighted Average Diluted Shares | 128↓2.2% | 131↓3.5% | 135↓2.4% | 139↑3.6% | 134 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.